Newbie Remogliflozin Gives Competition A Run For Their Money

Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.

Runners
Competition Heats Up In Indian SGLT2 market • Source: Shutterstock

Glenmark Pharmaceuticals Ltd.’s remogliflozin appears to have made noteworthy progress in India, with the new entrant garnering the highest prescriptions in the sodium glucose co-transporter-2 (SGLT2) inhibitor segment for the second month on the trot.

Remogliflozin (marketed as Remo) recorded 90,100 prescriptions in October 2019, higher than some established competitors such as Boehringer Ingelheim...

More from Business

More from Scrip